August 13, 2020 -- Anixa Biosciences and OntoChem have identified 26 additional compounds that target the main protease inhibitors of SARS-CoV-2.
The companies will continue to evaluate the 26 compounds and expect to synthesize multiple candidates for further testing. Dr. Amit Kumar, president and CEO of Anixa, noted the compounds are so novel that the companies have begun drafting a U.S. patent.
Axia and OntoChem previously used in silico screening to identify four compounds that could disrupt the function of endoribonuclease (also known as nonstructural protein-15; NSP-15). They will continue performing biological testing on the initial four molecules going forward, according to Dr. Lutz Weber, CEO of OntoChem.